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Abstract
Epstein-Barr virus (EBV) infection has been associated with different malignancies, and 
compelling evidence has shown that it may have a causative or at least contributing role 
in gastric carcinogenesis. EBV-associated gastric cancers have a unique molecular signa-
ture, which has defined this group of tumors as a distinctive molecular subtype of gastric 
cancer. This subtype has shown a greater incidence in the Americas than in the Asian 
countries. This chapter discusses about possible factors underlying these differences and 
the emerging roles of epigenetics in the pathogenesis of Epstein-Barr virus–associated 
gastric cancer.
Keywords: gastric cancer, Epstein-Barr virus, strains, phylogeographic diversity, epigenetic 
abnormalities
1. Introduction: an overview of the Epstein-Barr virus
Epstein-Barr virus (EBV) belongs to the human gammaherpesvirus and is a 175 kbp 
double-stranded linear DNA virus. EBV infection is associated with the development of 
different malignancies, including several lymphoid neoplasms like Burkitt’s lymphoma, 
Hodgkin’s lymphoma, and immunosuppression-related B-cell lymphoma; in addition, 
epithelial malignancies like nasopharyngeal carcinomas (NPC) and gastric carcinomas 
have also been associated with the EBV [1]. Primary EBV infection is most of the time 
asymptomatic, and like other members of the herpesvirus family, the EBV maintains its 
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genome as extrachromosomal circular episomes with repression of genes involved in 
virus replication. If latent persistent infection is established, viral reactivation may occur 
with the expression of specific EBV genes defining the type of latency in the infected cell. 
Genes involved in these patterns are shown in Figure 1 and include the EBV-encoded 
RNAs (EBERs), the EBV nuclear antigens (EBNAs), the BamH1-A rightward transcripts 
(BARTs) and the latent membrane protein (LMP)-1, 2A and 2B [3]. These latency-associ-
ated patterns have been associated with specific malignancies and in the case of gastric 
cancer, the virus shows a latency type I/IIab. The EBERs 1 and 2 genes are the most abun-
dant small noncoding RNAs that interact with proteins of the host and are the standard 
target for EBV detection by in situ hybridization (ISH) [4]. The EBNA-1 and -2 genes are 
exclusive nuclear proteins expressed in latent infected gastric carcinoma cells and related 
to the disruption of promyelocytic leukemia nuclear bodies [5]. EBNA-1 is a DNA-
binding protein that lacks enzymatic activity although it can interact with some cellular 
proteins such as CK2 and P32/TAP [6]. Interestingly, EBNA-1 is expressed in all of the 
EBV-associated tumors and is involved in viral DNA replication, mitotic segregation and 
transcriptional activation [7]. BART genes encode highly expressed multispliced RNAs 
whose protein-coding function is controversial [8]. Although some BARTs open reading 
frames (ORFs) have been predicted, currently it is not clear if any of them can be endog-
enously translated. In addition, BART genes, small as well as long noncoding RNAs, are 
highly expressed and associated with oncogenic transformation and immune evasion 
Figure 1. Gene expression patterns at different stages of EBV latency states. The theoretical progression of EBV latency 
gene expression from initial infection to true latency is described from left to right. The EBV genome is shown in episomal 
form closed at the terminal repeats (TR). Promoters are shown as white boxes and include the EBNA promoters Cp, Wp 
and Qp as well as the bidirectional LMPp. Primary mRNA transcripts are shown as dotted lines, while coding regions 
have been simplified as colored boxes. An expanded list of viral genes expressed in each latency state is listed directly 
underneath the representative schematic. Taken from [2] with permission.
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functions [9, 10] (for review, see [3, 11]). The LMP-1 and -2 encode for transmembrane 
proteins with a plethora of oncogenic functions with conflicted results in gastric carci-
noma (for review, see [12]). It has been proposed that variations in its sequences might 
be related to phylogeographic diversity of EBV-associated gastric carcinoma (EBVaGC) 
strains worldwide [13]. Taken together, EBV latent genes not only define the type of 
latency but also are associated with oncogenic transformation, immune evasion and the 
genetic diversity of EBVaGC.
2. Gastric cancer: novel molecular classifications
The molecular bases of gastric cancer have begun to be unraveled by a comprehensive 
molecular evaluation of primary tumors [14–20]. As shown in Figure 2, the Cancer Genome 
Atlas (TCGA) network has proposed a novel molecular classification of gastric carcinoma 
that recognized for the first time a subtype of tumor positive for Epstein-Barr virus, the EBV-
associated gastric carcinoma (EBVaGC). This novel subtype of gastric cancer is characterized 
by frequent PIK3CA gene mutations, amplification of JAK2, CD274 (PD-L1) and PDCD1LG2 
(PD-L2), and a unique CpG island methylator phenotype (CIMP) [14, 21].
Figure 2. Major features of molecular classification of gastric cancer as proposed by the tumor cancer genome atlas 
(TCGA) are CIMP: CpG island methylator phenotype, EBV: Epstein-Barr virus, MSI: microsatellite instability, GS: 
genomically stable and CIN: chromosomal instability. Taken from [20] with permission.
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3. EBV-associated gastric carcinoma: the Americas’ perspective
Worldwide studies show higher EBVaGC prevalence in the Americas than in Asia [22]. 
These observations suggest a phylogeographic diversity of Epstein-Barr virus strains along 
with host and environmental associations [13]. In the Americas, the first report of gastric 
tumors positive for Epstein-Barr virus comes from Shibata and coworkers [23] (Figure 3). 
These authors, based on the histological resemblance between rare variant of undifferen-
tiated gastric carcinomas with intense lymphoid infiltration (so-called lymphoepitheli-
oma-like carcinoma [LELC]) and nasopharyngeal lymphoepithelioma, a well-established 
EBV-associated disease, detected EBV sequences in seven of eight LELC cases. EBV genomes 
were uniformly present only in carcinoma cells but not in reactive lymphoid infiltrate or 
normal gastric mucosa. Furthermore, the presence of a single genotype in each LELC cell 
was consistent with a clonal process, suggesting that EBV infection occurs before malig-
nant transformation. Later, the same group expanded these findings to conventional gas-
tric cancer, detecting EBV sequences in 22 of 138 (16%) cases [24]. In all these cases, the 
EBV genome was expressed, exclusively in gastric tumor cells. No EBV sequences were 
detected in surrounding lymphocytes, or precancerous lesions such as intestinal metaplasia 
and chronic gastritis. In addition, EBVaGC cases were most often detected in males than in 
females (p = 0.007). To define the clinicopathological characteristics of this novel molecular 
Figure 3. A consolidated overview of EBVaGC in the Americas. Phylogeographic diversity of EBV strains along with 
host and environmental associations might explain the high incidence of EBVaGC in the Americas [24–31].
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subtype of gastric cancer, a long-term, well-characterized cohort of Japanese-Americans liv-
ing in Hawaii [32, 33] was evaluated. Unfortunately, beyond male predominance, no other 
clinicopathological characteristic, including survival, was found [32]. A high incidence of 
EBVaGC has been reported in Santiago, Chile, with 31 (16.8%) EBV-positive cases identi-
fied among 185 consecutive gastric cancer patients [25]. In this series, associations with the 
diffuse-type histology (p < 0.001) and nonantrum location (p = 0.01) were the most significant 
findings. Among Mexican descendants living in the USA, Gulley and coworkers and Vo and 
coworkers have reported 20 out of 138 (14.5%) EBVaGC cases [26, 27]. Interestingly, preva-
lence of EBV was 26.4% among Mexican descendants in comparison with 4.5% among white/
non-Hispanic cases. In addition, male predominance was found exclusively in those with 
Hispanic ancestry (p = 0.01) [27]. Koriyama et al. [28] examined 151 non–Japanese-Brazilian 
and 149 Japanese-Brazilian gastric carcinoma cases to identify an 11.2% prevalence among 
non–Japanese-Brazilian but only 4.7% among Japanese-Brazilian residents (p = 0.01). EBV-
associated gastric carcinoma was predominant in males only in the non–Japanese-Brazilian 
cases (p = 0.047). Taken together, these findings suggest human phylogeographic diversity 
in the prevalence of EBVaGC.
Among other countries in Latin America, Carrascal et al. [29], in Cali, Colombia, examined 
178 consecutive gastric carcinoma cases identifying 23 (13%) cases of EBVaGCs. In this 
series, EBVaGC also revealed a male (p = 0.004) and nonantrum (p = 0.009) predominance. 
Herrera-Goepfert et al. [30] identified 24 of 330 (7.3%) cases in Mexico City. In this series, 
no male predominance was confirmed, although all cases were of diffuse-type histology. 
The lowest frequency reported in Latin America was in Peru, where 254 gastric cancer 
cases from Japanese descendants were evaluated by Yoshiwara et al. [31]. In this analysis, 
only 3.9% (10 cases) of EBV infection was found, with no male or histological subtype 
predominance detected. A consolidated overview of EBVaGC in the Americas is shown in 
Figure 3.
A recent meta-analysis estimated a prevalence of 11.49% (95% CI = 8.46–15.43), with high 
heterogeneity among the aforementioned studies (I2 = 73.3%; p < 0.001). Although heteroge-
neity for predominant sex, location and histology was low (I2 = 16.5% [p = 0.35], 0% [p = 0.68] 
and 33.7% [p = 0.16], respectively), these authors showed male predominance (p < 0.001) and 
diffuse-type histology (p < 0.001) as the most significant features of EBVaGC in the Americas 
(Figures 4 and 5) [13].
In Asia, low prevalence of EBV-associated gastric carcinoma has been described. The 
reported prevalence ranges from 6.1% in Northern China [34] to 9.1% in Southern China 
[35]. In Japan and Korea, the reported prevalence is 6.6 and 6.9%, respectively [35, 36]. 
Among European countries, Russia and the Republics of the former Soviet Union, 8.7% 
prevalence has been reported [37]. Interestingly, distribution of EBV-positive GCs by sex, 
site and histological type was similar to that in Japan. In a study carried out in Holland, 
EBV was detected in 7.2% of the gastric carcinomas from the Dutch D1D2 trial (N = 566; 
mean follow-up, 9 years) [38]. In France, only 5.8% of 85 cases of gastric adenocarcinomas 
were EBV-associated adenocarcinomas, from which 4 cases were of the intestinal histo-
logical type [39].
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4. EBV strains and EBV-associated gastric carcinoma
Previous restriction fragment length polymorphism (RFLP) studies and the recently completed 
genome sequencing of 31 viruses head to the first global approach of the diversity of EBV. 
Seven of these sequences were obtained from healthy donors or benign lesions and twenty-five 
from strains present in tumors including nine EBVaGC [40–44]. By this approach, the genome 
diversity of EBV can be classified into five types (A–F). A substitution of 1.8 kb in the C-terminal 
part of the EBNA-2 gene defines types A and B [45]. Subtype A is the most common strain in the 
West and in Asia, while subtype B is the most common one in Africa [45, 46]. Polymorphisms at 
Figure 5. An estimated odds ratio (95% CI) for diffuse-type histology of EBV-associated gastric carcinoma in the 
Americas. Meta-analyses were performed by a random effects model with the inverse variance method, using the 
DerSimonian-Laird estimator, a logit transformation and the Clopper-Pearson confidence interval for individual studies. 
The results are shown in a log-scale. Taken from [13] with permission.
Figure 4. An estimated odds ratio (95% CI) for male predominance of EBV-associated gastric cancer in the Americas. 
Meta-analyses were performed by a random effects model with the inverse variance method, using the DerSimonian-
Laird estimator, a logit transformation and the Clopper-Pearson confidence interval for individual studies. The results 
are shown in a log-scale. Taken from [4] with permission.
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BamHI W1/I1 boundary region identify C and D subtypes. The lack of the BamHI site defines 
subtype C that predominates in Asia among healthy people and EBV-associated diseases [47–
50]. On the other hand, the presence of the BamHI restriction site defines subtype D that prevails 
in the West [47, 51]. Lastly, polymorphism at BamHI site identifies subtype F with worldwide 
distribution. However, the presence of an extra site defines the “f” variant and is found only in 
cases of nasopharyngeal carcinomas (NPC) [52]. Two more variants of EBV associated with the 
LMP-1 gene have been described. Polymorphisms at XhoI restriction site in position 169,425 of 
the LMP-1 gene define Western and Asian strains. Healthy people and EBV-associated diseases 
in Asia lack the XhoI restriction site [47], while in Western countries, the presence of the XhoI 
site is frequent [53]. The second variant in the LMP-1 gene is the deletion of 30-base pair at 
C-terminal (position 168,287–168,256) [54]. This variant confers an aggressive clinical behavior 
in Hodgkin’s disease [55].
In the Americas, both polymorphisms at BamHI W1/I1 boundary region (C and D types) and 
XhoI RFLPs at exon 1 of the LMP-1 gene are present in healthy donors at similar proportions 
[56]. These authors also identified two unique novel recombinant strains (C type/kept XhoI 
site and D type/lack of XhoI site) [56]. As shown in Figure 3, these findings might reflect the 
mixing of different ethnic populations in this continent as has been reported in Texas and 
Louisiana, USA [26, 27] and Brazil [28]. Conversely of what has been found in Asian and 
Western countries, this mixing did not reflect in the case of EBVaGC, since almost all EBV 
strains studied in tumors harbored exclusively the western genotype (D type and kept XhoI 
site) (OR 16.3 [95% CI 2.5–685]) [56]. Figure 3 shows a consolidated overview of phylogeo-
graphic diversity of Epstein-Barr virus strains in the Americas.
5. Epigenetic abnormalities of EBV-associated gastric carcinoma: DNA 
methylation
EBV-associated gastric cancer has been reported as the most extensive CpG island methyla-
tion at both human and viral genomes, being more extensive than any other tumor type 
from the TCGA network [14, 21, 57, 58]. CpG island methylation is an epigenetic mecha-
nism of gene expression regulation, affecting all cellular pathways [59]. It consists of methyl 
groups attached to the 5′ position of cytosines, which are followed by a guanine nucleotide 
(CpG site) [60] (Figure 6). More than 50% of human genes contain CpG site in the pro-
moter region and are known as CpG islands [62]. Methylation of CpG sites within a pro-
moter region may inhibit the binding of transcription factors in their consensus sequence 
of tumor suppressor genes, thus precluding the transcription of the gene, and resulting in 
gene silencing [63]. Methylation of tumor suppressor genes is usually seen at early stages 
of gastric cancer and increases during the stomach carcinogenesis [64]. These observa-
tions suggest that the silencing of these genes by DNA methylation mechanisms plays an 
important role in the gastric carcinogenesis. In addition, aberrant methylation is unusually 
detected in EBVaGC nonneoplastic surrounding mucosa, which might indicate a critical role 
of EBV in tumorigenesis mechanisms [65]. Although the extensive CpG island methylation 
is present in EBVaGC, a distinctive pattern of methylation has been suggested, as promoter 
methylation of tumor suppressor gene CDKN2A, but not promoter methylation of MLH1, 
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characteristic of the microsatellite instability (MSI) GC subtype [21, 27, 66–71]. Individual 
methylation of p14ARF and p16INK4a, alternative reading frames of CDKN2A locus, has 
also been described, and many studies have proved a significant association between their 
methylation and EBV positivity [72, 73]. Ushiku et al. [74] observed a uniform methylation 
of all CpG sites on promoter regions of both genes in EBVaGC, whereas it was variable in 
EBV-negative tumors. In addition, methylation frequency of p16INK4a appears to be about 
three times higher in EBVaGC than in EBV-negative tumors [65, 75]. CDH1, p15 and p73 
tumor suppressor genes are also frequently methylated in EBVaGC, representing one of the 
most common abnormalities described in this tumor [65, 74].
Despite EBV-induced host gene methylation in EBVaGC is well established, the exact under-
lying mechanisms are not entirely understood. It has been proposed that when the host cell 
detects the viral genome, it defends itself by starting a host-driven extensive methylation of 
the foreign genome, which may trigger the subsequent host genome methylation [75–77]. 
However, based on the specific methylation patterns observed, a possible participation of 
EBV in maintenance and de novo methylation has been proposed [72, 74]. Several studies 
have shown that EBV can modulate the expression of DNA methyltransferases (DNMT), 
which catalyze the transfer of methyl groups to DNA. Specifically, LMP-2A, EBV latent 
gene, has been shown to upregulate DNMT1 and DNMT3b expression in gastric cancer cell 
lines, which further induced methylation of several tumor suppressor genes, such as PTEN 
[78, 79]. Therefore, LMP-2A may play an essential role in the epigenetic abnormalities in host 
cells and in the development and maintenance of EBV-associated cancer.
Figure 6. DNA methylation. (A) CpG methylation mechanism is mediated by DNA methyltransferases and consists in 
the addition of a methyl group to the carbon in the 5th position of cytosines that precedes guanine nucleotides. (B) CpG 
islands are DNA sequences rich in CpG sites (>50% CpG sites within a 200bp sequence). Methylation of CpG islands 
inside a promoter region may control gene expression.
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6. Epigenetic abnormalities of EBV-associated gastric carcinoma: 
microRNAs
MicroRNAs (miRNAs) are small (~22 nt) noncoding RNAs and fundamental in posttran-
scriptional regulation of a broad range of biological processes of different organisms. This 
fundamental regulation is achieved through specific complementary binding to the 3′ 
untranslated region (3′UTR) of one or more target mRNAs, allowing regulation of multiple 
genes simultaneously [80] (Figure 7). Increasing evidence has shown that dysregulation of 
specific miRNAs has a crucial role in tumorigenesis. In fact, microRNAs involved in this 
process are usually called oncomiRs and anti-oncomiRs, acting similar to onco- and tumor-
suppressor genes [11]. Particularly, in gastric cancer, cellular miRNAs have gained special 
interest because they have shown differential expression between distinct cancer subtypes 
and have been related to progression and prognosis of the disease (for a review, see [80]). 
Viral microRNAs were first described in EBV [81]. It is now known that diverse virus  families 
Figure 7. Canonical pathway of miRNA biogenesis in human. miRNAs are transcribed by RNA polymerase II (RNAP 
II) from intergenic, intronic or polycistronic loci to long primary transcript, called primary miRNA (pri-miRNA), which 
consists in a stem, a terminal loop and single-stranded RNA segments at both the 5′- and 3′-UTR sides. Microprocessor 
complex (Drosha and DGCR8 cofactor) cleaves the stem-loop and releases a small hairpin-shaped RNA, called precursor 
miRNA (pre-miRNA). Following, pre-miRNA is exported into the cytoplasm by the transport complex formed by 
protein exportin 5 (EXP5) and GTP-binding nuclear protein RAN•GTP. Subsequently, pre-miRNAs are cleaved by a 
ternary complex formed by dicer, TAR RNA-binding protein (TRBP) and protein activator of PKR (PACT), producing a 
small RNA duplexes (miRNA-miRNA*). Next, these are loaded onto an Argonaute protein (AGO) to form an immature 
RNA-induced silencing complex (RISC) or pre-RISC, in a process mediated for heat shock cognate 70 (Hsc70)-heat shock 
protein (Hsp90) chaperone complex. AGO protein separates the two strands to generate a mature RISC effector. Finally, 
RISC binds the target mRNA through complementary binding of six to eight base pairs of the miRNA, with a specific 
sequence of the target resulting in the gene silencing. Taken from [80] with permission.
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encode miRNAs and that they are capable of targeting both cellular and viral genes [82]. 
EBV-miRNA expression is dependent on the host cellular miRNA processing machinery for 
its biogenesis. EBV miRNAs are encoded in two clusters within the EBV genome. As shown 
in Figure 1, the first cluster is localized in the Bam HI fragment H rightward open read-
ing frame 1 (BHRF1) gene and originates four mature miRNAs, which express only during 
lytic infection and in latency type IIb/III [83]. The second cluster is localized among the Bam 
HI-A region rightward transcript (BART) gene, encoding 40 mature miRNAs [84], which 
are expressed in all EBV latency types [83]. However, variable expression patterns of BART 
miRNAs have been reported in different EBV-associated malignancies or cell types [83, 85]. 
Additionally, discrepant reports exist concerning specific BART miRNAs’ relative expression 
within the same cellular context, which could be in part a result of different EBV strains stud-
ied [86–89]. Most BART miRNAs host targets, identified so far, are involved in proapoptotic 
and immune response pathways, suggesting a crucial role in promoting host cell survival 
[90]. For instance, EBVaGC highly expressed miRBART4-5p and miRBART5-5p that have 
been shown to target and downregulate the BH3-interacting domain death agonist (BID) 
protein [91] and the p53-upregulated modulator of apoptosis (PUMA) [92], respectively. 
Furthermore, EBV not only expresses its own miRNAs but also alters miRNAs’ expression of 
the host cells. Particularly, miR-200 family has been shown to be consistently downregulated 
both in GC cell lines and in EBVaGC tumor samples compared to normal adjacent mucosa 
and other GC subtypes [93, 94]. Aberrant DNA methylation following EBV infection and 
viral proteins such as BRAF0, EBER, and LMP-2A have been proposed as the main mecha-
nisms of downregulation of these miRNAs [93, 95].
7. Summary and conclusions
Novel molecular classifications and meta-analyses identified Epstein-Barr virus (EBV) as a 
distinct etiological agent for gastric cancer. An important characteristic of EBV-associated 
gastric carcinoma (EBVaGC) is the difference in incidence in Asia and the Americas. Specific 
EBV genes such as EBERs, EBNAs, BARTs and LMP are the most actively expressed in 
EBVaGC, and variations in its sequences might be associated with phylogeographic diversity 
of EBV strains across the world. Polymorphisms at BamHI W1/I1 boundary region and XhoI 
RFLPs at exon 1 of the LMP-1 gene have been found in healthy donors reflecting the mixing of 
different ethnic populations in the Americas. However, this is not the case for gastric cancer, 
since almost all types of EBVaGC studied harbor exclusively the western genotypes (subtype 
D and kept XhoI site). These findings propose that a disrupted coevolution between a patho-
gen and its healthy population might contribute to a phylogeographic origin of disease. DNA 
methylation and cellular and viral microRNAs play an emerging role in the pathogenesis of 
EBVaGC.
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